Gilead Sciences (NASDAQ:GILD) executive Dr. Franck Rousseau has been named chief medical officer of gastrointestinal drug development company Tranzyme Pharma (NASDAQ:TZYM).
Rousseau will oversee Durham, North Carolina-based Tranzyme’s drug portfolio including two clinical-stage candidates ulimorelin and TZP-102. Ulimorelin is studied in a phase 3 clinical trial as a drug that can help restore GI function after surgery. TZP-102 is in a phase 2b study as a diabetic gastroparesis treatment, a condition whose symptoms include nausea, satiety and bloating that can be caused by diabetes.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The chief medical officer position is a new one for Tranzyme. But Rousseau’s work will include taking over the responsibilities held by Dr. Gordana Koustic, Tranzyme’s former vice president of clinical and regulatory affairs. Koustic resigned from Tranzyme last month “to pursue another opportunity.”
Rousseau has more than 15 years in clinical and pharmaceutical research. Tranzyme CEO Vipin Garg said in a statement that the company will benefit from Rousseau’s experience filing new drug applications with regulators in the United States and Europe as well as his record in getting market approval for drugs.
At Gilead, Rousseau most recently worked as a therapeutic area head and vice president, hepatic diseases, where he oversaw the clinical development for several drugs that ultimately received global marketing approval. He has also worked as Gilead’s vice president, clinical research. Rousseau was CMO of Triangle Pharmaceuticals until its 2003 acquisition by Gilead. His experience includes work at Wellcome Lab in Paris, France and Glaxo Wellcome in Research Triangle Park, North Carolina.
Photo from Flickr user Rosmary
